Bicara Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Bicara Therapeutics Common
BCAX Stock   16.12  0.39  2.36%   
Bicara Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Bicara Therapeutics' valuation are provided below:
Market Capitalization
904.5 M
Earnings Share
5.38
Bicara Therapeutics Common does not presently have any fundamental signals for analysis.
Check Bicara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bicara Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 196.3 K, Net Interest Income of 15.3 M or Interest Income of 15.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.02. Bicara financial statements analysis is a perfect complement when working with Bicara Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Bicara Stock
Check out the analysis of Bicara Therapeutics Correlation against competitors.

Bicara Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets297 M569.2 M74.2 M
Slightly volatile
Other Current Liabilities11.5 M12.9 M17.5 M
Slightly volatile
Total Current Liabilities15.2 M18 M22.4 M
Slightly volatile
Property Plant And Equipment Net841.9 K845 K673.1 K
Slightly volatile
Accounts Payable3.4 M4.5 M4.9 M
Slightly volatile
Cash265.6 M489.7 M65 M
Slightly volatile
Non Current Assets Total70 M66.7 M10.1 M
Slightly volatile
Non Currrent Assets Other3.6 M6.6 M1.6 M
Slightly volatile
Cash And Short Term Investments265.6 M489.7 M65 M
Slightly volatile
Common Stock Shares Outstanding57.9 M54.4 M52.3 M
Slightly volatile
Liabilities And Stockholders Equity297 M569.2 M74.2 M
Slightly volatile
Non Current Liabilities Total62.3 M59.3 M7.7 M
Slightly volatile
Other Current Assets13.5 M12.8 M2.4 M
Slightly volatile
Other Stockholder Equity748.5 M712.9 M93.4 M
Slightly volatile
Total Liabilities42.8 M77.3 M28 M
Slightly volatile
Property Plant And Equipment Gross841.9 K845 K673.1 K
Slightly volatile
Total Current Assets270.8 M502.5 M66.8 M
Slightly volatile
Capital Stock4 K7 K2.4 K
Slightly volatile
Non Current Liabilities Other14.5 K15.3 K72 K
Slightly volatile
Common Stock4 K7 K2.4 K
Slightly volatile
Short and Long Term Debt Total767.2 K738 K669 K
Slightly volatile
Short Term Debt490.6 K607 K318 K
Slightly volatile

Bicara Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision196.3 K187 K25.1 K
Slightly volatile
Interest Income15.3 M14.6 M2 M
Slightly volatile
Depreciation And Amortization31.2 K56 K14.8 K
Slightly volatile
Selling General Administrative12.6 M18.8 M7.7 M
Slightly volatile
Other Operating Expenses58.6 M82.4 M41.9 M
Slightly volatile
Research Development46 M63.6 M34.2 M
Slightly volatile
Cost Of Revenue31.2 K56 K14.8 K
Slightly volatile
Total Operating Expenses58.6 M82.4 M41.9 M
Slightly volatile
Reconciled Depreciation31.2 K56 K14.8 K
Slightly volatile
Income Tax Expense196.3 K187 K25.1 K
Slightly volatile

Bicara Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.7 M7.4 M1.5 M
Slightly volatile
Begin Period Cash Flow242 M230.4 M33.6 M
Slightly volatile
Other Cashflows From Financing Activities1.5 M1.6 M43 M
Pretty Stable
Depreciation31.2 K56 K14.8 K
Slightly volatile
Capital Expenditures67.5 K71 K201.3 K
Very volatile
Issuance Of Capital Stock233.3 M332.4 M78 M
Slightly volatile
Total Cash From Financing Activities234 M334 M78.3 M
Slightly volatile
End Period Cash Flow265.6 M489.7 M65 M
Slightly volatile
Other Cashflows From Investing Activities49.6 K55.8 K60.8 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation1.21.267917.6819
Slightly volatile
Payables Turnover0.01510.01440.0038
Slightly volatile
Cash Per Share9.458.99791.4965
Slightly volatile
Days Payables Outstanding24.1 K25.4 K159.3 K
Slightly volatile
Income Quality0.751.09940.8591
Pretty Stable
Net Debt To EBITDA7.587.21711.2908
Slightly volatile
Current Ratio29.3327.9344.7058
Slightly volatile
Capex Per Share0.00120.00130.0039
Very volatile
Interest Debt Per Share0.00760.01360.0039
Slightly volatile
Debt To Assets0.00230.00140.0027
Slightly volatile
Days Of Payables Outstanding24.1 K25.4 K159.3 K
Slightly volatile
Ebt Per Ebit1.140.8231.0207
Pretty Stable
Quick Ratio29.3327.9344.7058
Slightly volatile
Net Income Per E B T0.81.00280.9877
Slightly volatile
Cash Ratio28.5827.22134.5837
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00091.0126
Slightly volatile
Debt Ratio0.00230.00140.0027
Slightly volatile

Bicara Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.2 B948.1 M1.2 B
Slightly volatile
Enterprise Value436.2 M459.1 M1.1 B
Slightly volatile

Bicara Fundamental Market Drivers

About Bicara Therapeutics Financial Statements

Bicara Therapeutics investors use historical fundamental indicators, such as Bicara Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bicara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue56 K31.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C

Additional Tools for Bicara Stock Analysis

When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY